head and neck cancer treatment update: pembrolizumab, nivolumab and pd-l1 markers
Published 7 years ago • 1.5K plays • Length 26:30Download video MP4
Download video MP3
Similar videos
-
2:31
low or negative pd-l1 head and neck cancertreatment options for patients - hpv advances
-
1:58
dr. vokes on nivolumab, pembrolizumab approvals in head and neck cancer
-
5:38
curable hpv negative head and neck cancer
-
4:11
data from keynote 12 - nivolumab and pembrolizumab
-
11:25
curable hpv positive head and neck cancer - head and neck cancer: panel discussion
-
11:47
curable hpv positive head and neck cancer
-
5:15
emerging treatment options for head and neck cancer - hpv advances
-
2:02
progression on pembrolizumab: patient without actionable mutations & low pd-l1 - lung cancer onctalk
-
1:00
dr. ferris on pembrolizumab and nivolumab in head and neck cancer
-
2:07
study results for nivolumab and pembrolizumab in head and neck cancer
-
3:46
immunotherapy treatments in patients with head and neck cancer - asco recaps head and neck cancer
-
9:38
advances in thyroid cancer treatment - head and neck cancer: panel discussion
-
11:57
current treatments and most promising clinical trials for head and neck cancer
-
2:32
hpv advances - current head and neck cancer treatments
-
9:13
induction chemotherapy for head and neck cancer, part 1: defining the challenges
-
2:00
keynote 671: perioperative pembrolizumab for nsclc - onctalk lung 2023
-
10:08
asco/esmo 2020 - head and neck cancer updates - javelin100 trial update
-
11:07
palliative care and studies for incurable head and neck cancers - 2021 asco esmo head & neck recap